Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after Atezolizumab/Bevacizumab Failure: A real-world study

CONCLUSION: In second-line therapy for unresectable HCC after ATE+BEV failure, lenvatinib showed better PFS and comparable OS to sorafenib in a real-world setting. Future studies with larger sample sizes and longer follow-ups are needed to optimize second-line treatment.PMID:38468561 | DOI:10.3350/cmh.2023.0553

Source: Clinical and molecular hepatology - March 12, 2024 Category: Gastroenterology Authors: Young Eun Chon Dong Yun Kim Mina Kim Beom Kyung Kim Seung Up Kim Jun Yong Park Sang Hoon Ahn Yeonjung Ha Joo Ho Lee Kwan Sik Lee Beodeul Kang Jung Sun Kim Hong Jae Chon Do Young Kim Source Type: research